As depicted in Fig. 1B, TYM-3–98 concentration-dependently reduced the phosphorylation of AKT (Ser473), mTOR, and S6, which is consistent with the positive control Idelalisib, illustrating that the activity of PI3K–AKT–mTOR pathway in CRC cells is blocked by TYM-3–98. Here, PIK3CB is linked to colorectal carcinoma.